Tech Times on MSN
With Vertex's FDA clock ticking, Vor Bio locks in a second-generation BAFF/APRIL autoimmune drug
Vor Bio expands its BAFF/APRIL drug franchise with a $56 million RemeGen deal for RC298, ahead of Vertex's FDA decision on ...
Good morning. This is the 20th issue of the AI Tech Morning Paper. We deliver the most important movements in AI and technology, condensed so you can catch up in just a few minutes of your morning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results